There was no significant statistical difference between over expression and Under expression of BCL2L12 in the studied adult AML bone marrow samples compared to the control BM samples as regard outcome of treatment on day 15 (P value:1), or relapse risk (RR) (P value: 0.1) and overall survival (P value:0.94). The gene discussed is BCL2L12; the disease is acute myeloid leukemia.